Forest, Gedeon report positive Phase III bipolar I disorder trial data
Forest Laboratories and Gedeon Richter have reported positive results from Phase III trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.
The trial data showed that cariprazine treated patients with acute manic episodes experienced significant improvements in symptoms compared to placebo-treated patients.
The results of this study were consistent with the results observed in the two previously completed pivotal placebo-controlled cariprazine studies in this patient population, the company said.
Cariprazine is also currently being investigated in clinical studies for patients with schizophrenia, bipolar depression, and as an adjunct treatment for Major Depressive Disorder.
Gedeon research director Zsolt Szombathelyi said in the three consecutive positive trials, statistically significant results demonstrated improvement in symptoms compared to placebo, importantly including the low dose range arm.
Related Insight
Suppliers Directory
Pro-Active Translations- Language Translations Specialist for Life Sciences
PA Translations focuses on providing best-in-class specialized translation services for companies in the pharmaceutical, medical device and laboratory instrument, and healthcare sectors in up to 75 languages.
Contract Research & Services > Clinical Trials > Suppliers
Centre for Human Drug Research - Early Phase Drug Development
The Centre for Human Drug Research (CHDR) performs clinical studies of innovative medicines with the concept where the maximum amount of information is extracted in the earliest clinical phase, using innovative and complex techniques as reflected in our publication output.
Contract Research & Services > Clinical Trials > Suppliers
CCL Label - Global Healthcare and Pharmaceutical Packaging Solutions
CCL Label is a Global Manufacturer of Pharmaceutical and Healthcare packaging. With 20 healthcare sites globally, we offer the expertise, trained personnel and dedicated production capabilities to ensure that your pharmaceutical/healthcare labelling is accurate, secure and meets all FDA requirements and current Good Manufacturing Practices (GMP)
Contract Research & Services > Clinical Trials > Suppliers
TSS - Temperature Sensitive Solutions
TSS is a leading provider of products and services for cold chain management, with focus on temperature monitoring. TSS has since its establishment in 1992, provided cold chain solutions to the pharmaceutical industry. The product portfolio contains the Cold Chain Information System (web based temperature monitoring system), CoolKeeper refrigerants and ProBox shipping containers.
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
Comprehensive Feasibility Assessments in Eastern Europe - Luxury or Necessity?
Published by Centrical Global Limited
Contract Research & Services > Clinical Trials > White Papers
Biotechnology Solution Brief
Published by Brainloop
Contract Research & Services > Clinical Trials > White Papers
A Study of the Psychomotor and Cognitive Impairments Produced by Diazepam as Measured by NES 2
Published by BioKinetic Europe
Contract Research & Services > Clinical Trials > White Papers
Oncology and Clinical Trials in the 21st Century
Published by BioClinica
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.